GlassScriptPhysician profile
Jack J Zhou
NPI 1265402168
$11,193.35
in general payments reported to CMS, 2019-2025
26 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $1,329 · 2021: $1,807 · 2022: $1,736 · 2023: $1,789 · 2024: $1,727 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,920 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,919.65 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,598.92 | 2019-2025 | Vemlidy |
| Abbvie INC. | $1,364.39 | 2019-2025 | Linzess, Viberzi, Creon |
| Amgen INC. | $1,140.13 | 2019-2025 | Tezspire, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,033.81 | 2019-2025 | Airsupra, Farxiga, Tezspire |
| Glaxosmithkline, LLC. | $994.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.82 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $657.03 | 2019-2025 | |
| Novo Nordisk INC | $652.31 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $625.34 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $570.40 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $405.26 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $248.78 | 2019-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $247.13 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $181.58 | 2019-2022 | |
| Astellas Pharma US INC | $139.92 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $133.69 | 2021-2023 | |
| Allergan, INC. | $123.48 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $98.04 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.78 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.77 | 2021-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $51.32 | 2023 | Rexulti |
| Insulet Corporation | $25.20 | 2024 | Omnipod |
| Exact Sciences Corporation | $24.51 | 2023 | Cologuard Collection Kit |
| Radius Health, INC. | $22.94 | 2019 | |
| Smith+Nephew, INC. | $15.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.